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AbstrACt
Introduction Psychological interventions and 
antidepressant medication can be effective interventions 
to prevent depressive relapse for patients currently in 
remission of depression. Less is known about overall 
factors that predict or moderate treatment response 
for patients receiving a psychological intervention for 
recurrent depression. This is a protocol for an individual 
participant data (IPD) meta- analysis which aims to assess 
predictors and moderators of relapse or recurrence for 
patients currently in remission from depression.
Methods and analysis Searches of PubMed, PsycINFO, 
Embase and Cochrane Central Register of Controlled 
Trials were completed on 13 October 2019. Study 
extractions and risk of bias assessments have been 
completed. Study authors will be asked to contribute IPD. 
Standard aggregate meta- analysis and IPD analysis will 
be conducted, and the outcomes will be compared with 
assess whether results differ between studies supplying 
data and those that did not. IPD files of individual data will 
be merged and variables homogenised where possible for 
consistency. IPD will be analysed via Cox regression and 
one and two- stage analyses will be conducted.
Ethics and dissemination The results will be published 
in peer review journals and shared in a policy briefing as 
well as accessible formats and shared with a range of 
stakeholders. The results will inform patients and clinicians 
and researchers about our current understanding of more 
personalised ways to prevent a depressive relapse. No 
local ethics approval was necessary following consultation 
with the legal department. Guidance on patient data 
storage and management will be adhered to.
PrOsPErO registration number CRD42019127844.
IntrOduCtIOn
Depression is a highly debilitating mental 
health problem, and one of the leading causes 
of disability worldwide.1 Depression or major 
depressive disorder (MDD) has a chronic 
course, and relapse rates are high.2 3 Approx-
imately 40%–60% of patients who develop a 
major depressive episode relapse, and this risk 
increases up to 90% after three episodes.4–7
Recurrence and relapse are terms 
frequently used synonymously to describe the 
reoccurrence of depressive symptoms.8 9 Both 
terms indicate a worsening of symptoms and 
onset of a new episode of depression after 
a period of no or subthreshold symptom-
atology. However, they do so at different time 
points after the initial episode.8 9 The clinical 
and scientific distinctions on these time cut- 
offs between relapse and recurrence were 
found to be unhelpful.10 Therefore we will 
use relapse to describe both recurrence and 
relapse in this manuscript.
Two types of interventions are recom-
mended for relapse prevention for remitted or 
recovered MDD patients; either continuation 
strengths and limitations of this study
 ► An individual participant data (IPD) analysis can be 
a superior method to standard meta- analyses, as it 
allows us to increase power to detect potential pre-
dictors and moderators of treatment.
 ► This is the first IPD meta- analysis which sets out to 
evaluate a wide range of psychological relapse pre-
vention interventions for depression.
 ► This, to our knowledge, is the largest IPD meta- 
analysis thus far to assess the effects of moderators 
on relapse and recurrence of depression.
 ► IPD meta- analyses are limited by the data available, 
which may limit the number of studies included 
and subsequently reduce statistical power and limit 
generalisability.
 ► Moreover, there may be inconsistencies in terms of 
how covariates are reported, limiting the number 
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of antidepressant medication (ADM) or psychological 
interventions.11 12 ADM or psychological interventions 
can be offered as a continuation following the therapy 
on which remission was achieved (continuation therapy), 
or as sequential interventions, where a different therapy 
is offered after (spontaneous) remission is achieved.4 13 14 
Mindfulness- based cognitive therapy (MBCT), preventive 
cognitive therapy (PCT) and wellbeing therapy (WBT) 
are examples of psychological relapse prevention inter-
ventions used in sequential therapy.2 4 13 15–19
A substantial proportion of patients still relapse even 
after having received a psychological intervention, ADM 
or a combination of these after remission to prevent 
relapse.19 20 It might be that some psychological interven-
tion types might be more effective, or they have varying 
levels of effectiveness for different patient characteristics. 
These characteristics can be separated into prognostic 
indicators and prescriptive factors.21 Prognostic factors 
affect the course of depression regardless of the treatment 
provided.21 Prescriptive factors, also called ‘moderators’, 
indicate differential treatment effects across patient char-
acteristics and can be used inform decisions as to which 
treatment may be best suited to someone with specific 
characteristics, such as continuation or sequential treat-
ment and/or indicated treatment approaches.21 22
A recent meta- analytic review of reviews found that, in 
recurrent depression, childhood maltreatment, previous 
depressive episodes, residual symptoms after treatment, 
co- occurring anxiety disorders as well as rumination 
were among the strongest prognostic factors in recur-
rent depression.23 In terms of moderators, there was less 
evidence to suggest any variable could affect treatment 
selection. Some evidence suggests that residual symptoms 
at baseline may be potentially be reduced more by cogni-
tive behavioural therapy (CBT) compared with ADM and 
patients with a history of severe childhood maltreatment 
may respond better to MBCT compared with treatment as 
usual (TAU).23 However, it remains unclear whether treat-
ment outcomes can be improved if certain interventions 
are offered to patients with these characteristics.4 23 24
An individual participant data (IPD) meta- analysis can 
provide a unique insight into treatment effectiveness and 
the effect of individual- level moderators on treatment 
outcome.25 26 IPD analyses are relatively new in the field of 
clinical psychology and psychiatry.27 28 They can provide 
a more accurate estimate of the true treatment effect and 
help identify which interventions work better or worse 
in specific subgroups of patients.26 The use of IPD from 
multiple studies combined can increase the power to 
detect which patients respond best to treatment within 
and across studies, something which cannot be assessed 
with aggregate trial information alone.29 Besides, an 
IPD meta- analysis can adjust for study- level confounding 
factors which may bias the result of a traditional aggre-
gate meta- analysis.30
To our knowledge, only one IPD meta- analysis evalu-
ating psychological interventions versus control for recur-
rent depression has been conducted thus far.31 In this IPD 
meta- analysis, Kuyken and colleagues estimated the effec-
tiveness of MBCT versus control (active or non- active) and 
aimed to establish the effect of moderators on treatment 
outcome. Among nine included studies with 1258 partici-
pants, the authors performed a time to event (depressive 
relapse) IPD meta- analysis which produced an HR of 0.69 
(95% CI 0.58 to 0.82), indicating a reduced risk of relapse 
in those participants who received MBCT compared 
with participants in the control group. No differential 
treatment effects across participant characteristics were 
found. In this review, depression baseline scores (indic-
ative of incomplete recovery) predicted a stronger effect 
at follow- up. Thus, patients with higher symptomatology 
at the start of treatment seemed to benefit most. Kuyken 
et al31 only included MBCT, a range of other forms of 
psychological interventions were not included (ie, CBT, 
PCT or interpersonal therapy). Including these would 
increase power to assess moderators of treatment, estab-
lish effects of different psychological interventions versus 
control, as well as allow for an evaluation of the interac-
tion between therapy type and moderator.
This study aims to answer three research questions 
which remain pertinent from the literature, namely:
1. What are the effects of different preventive psychologi-
cal interventions on reducing the risk of relapse versus 
control?
2. What are the predictor variables associated with an in-
creased risk of relapse for patients receiving a psycho-
logical intervention?
3. What factors (moderators) may predict which partici-
pant responds best to which type of intervention?
MEthOds
General approach
This IPD meta- analysis is registered on PROSPERO and 
any key changes or amendments will be documented there. 
The protocol is registered retrospectively as searches and 
aggregate study- level extractions were already conducted 
in 2018, and the last search was conducted on 13 October 
2019. The Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses IPD statement will be followed 
for the reporting of this study.32
systematic review to identify eligible papers
Eligibility criteria
Types of studies
Eligible studies must have a randomised controlled study 
(RCT) design and be written in the English language.
Types of interventions
Included studies will examine the effects of psycholog-
ical relapse prevention interventions, and we used the 
following definition: ‘a modality of treatment in which 
the therapist and patient(s) work together to ameliorate 
psychopathological conditions and functional impair-
ment through focus on the therapeutic relationship; the 
patient’s attitudes, thoughts, affect and behaviour; and 
social context and development’.33 The intervention 
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can be delivered in any modality or setting, such as 
face to face, in a group format or online. Examples 
include MBCT, PCT, continuation cognitive therapy, or 
WBT.13 14 17 19 34 Sequential treatment combinations, that 
is, studies where a different relapse prevention therapy 
starts directly after treatment for acute depression,13 14 
will be included as long as patients were randomised to 
a relapse prevention intervention after reaching remis-
sion or recovery (as defined by the study authors) from 
the acute episode. As we are interested in the overall 
effect of psychological interventions versus control, 
studies where participants were randomised to taper 
from ADM as they receive the psychological interven-
tion will be excluded.
Types of comparators
To answer our first question (estimate of treatment 
effect), at least one non- psychotherapeutic control group 
should be available. Eligible control conditions include 
TAU, ADM and active psychological control group. For 
our second question (prognostic indicators) for patients 
receiving psychological interventions, any control group 
can be included. For our third question (moderator anal-
ysis), which assesses what works for whom, at least one 
non- psychological control group should be available.
Types of participants
Participants aged 18 and over were included. Studies, 
where participants were only included if they had an 
onset after the age of 65, were excluded. As also specified 
by Brouwer (2019), the factors causing and contributing 
to the first onset of depression in the 65 and above age 
range may differ from lower age groups.35–37 Participants 
in trials need to have had at least one prior diagnosis of 
MDD established by an independent clinical interview 
and/or healthcare provider who was not involved in the 
study. The randomisation and subsequent treatment or 
TAU should have been during the remission, response or 
recovery phase. Participants were required to be in remis-
sion from at least one episode of MDD. Remission is clas-
sified as a period of at least 8 weeks, where participants 
had no or subthreshold clinical symptoms.4 38 Sequential 
treatment combinations were included as long as partic-
ipants in the intervention group achieved remission or 
response according to the authors of the study. Studies 
were excluded when participants were in treatment for 
another mental disorder as classified by the Diagnostic 
and Statistical Manual of Mental Disorders (DSM)- V, 
DSM- IV, or DSM- III criteria.39 40 41
Outcomes
Primary outcome
The primary outcome of the study will be time to depres-
sive relapse at any point of follow- up measured in weeks. 
Depressive relapse needs to be determined via an inde-
pendent examiner/assessor via a diagnostic interview, for 
example, the Structured Clinical Interview for DSM- IV 
Axis 1 Disorders,42 the Mini- International Neuropsychiatric 
Interview,43 44 the Composite International Diagnostic 
Interview45 or the Hamilton Depression Rating Scale.46
Covariates
We are interested in patient characteristics which predict 
relapse of depression regardless of treatment allocation 
(predictor variables), and those that may affect outcome 
based on treatment allocation (moderators). Sometimes 
these terms are used interchangeably. However, in this 
manuscript we use these terms to differentiate between 
overall treatment outcome predictors and factors moder-
ating treatment response (ie, who responds better to one 
treatment vs a control condition or vice versa). Patient 
characteristics will be included in the analyses if they are 
consistently reported and available across datasets and 
justify inclusion based on prior literature that identifies 
them as potential predictors or moderators.4 23 47
We will ask the individual studies to provide data on the 
following set of variables which could either be predictors 
or moderators of effect.
Age at baseline, gender, ethnicity, country of birth, 
education status, employment status, marital status, 
number of previous depressive episodes, age of onset 
of first episode of depression, time spent in remission 
since last episode, duration of past episode of depression, 
stable or unstable remission since last episode, history 
of childhood trauma, previously received psychotherapy 
for MDD (including type and time since last session), 
previously received medication for MDD (including type, 
dosage and time since last intake), comorbid anxiety 
disorder, comorbid mental health disorder, comorbid 
physical health disorder, antidepressant exposure at 
baseline, baseline depression symptoms, baseline anxiety 
symptoms, baseline quality of life symptoms.
Timing of outcome measures
The primary outcome, time to depressive relapse, will 
be included for all participants, regardless of variation 
in follow- up duration across studies. We will consider 
censoring follow- up time, for example at 60 weeks, contin-
gent on the length of follow- up across studies.
Secondary outcomes
Secondary outcomes include depressive symptomatology 
at follow- up, anxiety symptoms and quality of life. These 
will be collected and may be used for future analysis.
searches for study identification and selection
PubMed, PsychINFO, Embase and Cochrane Central 
Register of Controlled Trials were searched. Index and 
free terms, jointly with Boolean operators, were used on 
four tiers, namely: (1) depressive disorder, (2) recurrence 
and relapse, (3) preventative interventions, (4) RCT. 
Online supplementary appendix 1 shows the search terms 
for PubMed. References from previous meta- analyses 
were screened to ensure no RCTs are missing.14 19 48–51 Key 
authors in the area of relapse prevention for depression 
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The last searches for this IPD were completed on 13 
October 2019, three researchers independently screened 
search results (JB screening all and a research assistant 
or collaborator conducting the second screen). Full- text 
screens were conducted by two independent researchers. 
Outcome data for all studies are being extracted inde-
pendently by at least two independent researchers and 
are then being merged and checked by JB. Discrepancies 
were discussed with the researchers involved in extraction 
and resolved via discussion with MB.
Quality assessment
Study quality will be assessed by two reviewers who will 
independently evaluate the studies based on six criteria 
for risk of bias from the Risk of Bias tool by the Cochrane 
Collaboration.52 53 The following criteria will be assessed: 
(1) random sequence generation; (2) allocation conceal-
ment; (3) blinding of outcome assessors; (4) incomplete 
outcome data; (5) selective outcome reporting; (6) 
other threats to validity (similar groups, cointerventions, 
compliance and similar timing of outcome assessment). 
Studies will be rated on each criterion with either ‘low 
risk’ ‘high risk’ ‘unclear risk’. A minimum of five criteria 
with a ‘low risk’ rating qualified as the overall low risk of 
bias. Only data that are published in the full- text paper 
of the trial will be evaluated and assessed by two inde-
pendent assessors, to avoid potential imbalance between 
studies that can share data and those that are not able to 
do so.
Patient and public involvement
During the development of this protocol, no direct 
patient involvement has taken place. However, we are 
planning to consult with people with lived experience 
during the interpretation and dissemination of the study 
results. Results will be disseminated in peer review jour-
nals but also a coproduced evidence briefing in collabo-
ration with the Mental Health Foundation. We have set 
up a consortium of all collaborating authors on this IPD 
(and other researchers as well as other stakeholders inter-
ested in relapse prevention of depression) titled "Inter-
national Taskforce For RelApse prevention of depression 
(ITFRA)". This taskforce aims to help disseminate the 
research and raise awareness with the public and clinical 
community.
IPd data collection and aggregation
Invitation of authors
All corresponding authors of the selected articles for inclu-
sion will be contacted via email by the senior authors of this 
article with an invitation to participate in the study. The 
letter includes details regarding the study group, the study 
proposal, the goals of the analysis, the variables of interest 
and includes a request to share raw data from the trial partic-
ipants for this study. When there is no response from the 
author within 4 weeks, we will try a second time. If this fails, 
a second senior author will be contacted. We will continue 
until we have reached at least three authors. If none of 
the authors responds or if all the authors indicate that the 
data are unavailable or that they are unable to share due to 
access restrictions, it will be noted that the study data were 
unavailable. We will send a maximum of four reminders 
until we exclude the study as being unavailable.
Data checking and integrity
After accepting the invitation to collaborate and signing 
the data transfer agreement, the authors will be asked to 
share their data via a secure data transfer portal available 
to the Amsterdam University Medical Centre—Location 
AMC. The received data will be reviewed to assess the 
completeness and accuracy of the dataset. If any incon-
sistencies are present (missing data, inconsistencies or 
extreme values, discrepancies between the trial report 
and the data), the issue will be discussed with the study 
authors who will be contacted for clarification. The study 
progress and discrepancies will be recorded.
Creating a database and aggregation
A template spreadsheet with study characteristics and 
outcome data will be created. Once data have been checked 
and standardised, it will be merged into the final file for 
analysis. All individual datasets will be merged into one large 
IPD dataset. Once all data have been merged into a final 
dataset, it will be rechecked for accuracy by a researcher in 
the study team, by comparing participant numbers, descrip-
tive data and relapse/recurrence data to the reported data 
in the peer- review article.
statistical analysis
To determine the final selection of potential predictors 
and moderators, we will identify reported covariates 
across studies and identify ways that covariates can be 
appropriately standardised across studies, for example, by 
collapsing categories. Baseline covariates will be included 
in the modelling if the covariate has at least 40% available 
data (ie, non- missing) in at least three studies.54
To examine the overall effects of the interventions 
compared with control (research question 1) and assess 
the modifying effect of study and individual- level variables 
on prognostic and predictive value (research questions 2 
and 3), we will conduct one- stage and two- stage random- 
effects IPD meta- analyses using Stata v.14.55
Our primary meta- analysis method will be the one- stage 
random- effects approach; we will seek to perform one- 
stage random- effects meta- analyses for the time to event 
outcomes using hierarchical flexible parametric models.56 
A random- effects meta- analysis was chosen because we are 
aware of clinical heterogeneity in the included trials (eg, 
due to differences in study populations, types of psycho-
therapy, or differences in the control group), which may 
result in statistical heterogeneity. Should such models fail to 
converge, we will then perform Cox proportional hazards 
models stratified by study (one- stage fixed effect approach).
A two- stage method for time to event data calculates 
the HR for relapse for each study individually, using a 
Cox proportional hazards model; these HRs will then be 
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combined in the IPD meta- analysis. If only rate ratio data 
are available, we aim to calculate an estimate of HR data 
from rate ratio data by the logarithms of event- free propor-
tions.57 We will use the DerSimonian and Laird58 random 
effects method to combine the results of the individual 
studies and will apply the Hartung Knapp- Sidik- Jonkman 
method correction to account for uncertainty in τ2.59 60
We aim to answer our first research question (esti-
mate of effect) via an IPD meta- analysis on a maximum 
of four pairwise comparisons: (1) psychotherapy versus 
ADM, (2) psychotherapy versus TAU, (3) psychotherapy 
versus active control (ie, placebo or active psycholog-
ical intervention), (4) psychotherapy versus any non- 
psychotherapy control. All analyses will use the intention 
to treat approach, whereby all participants will be included 
in the analyses according to their randomised allocation 
irrespective of treatment received. Primary analyses will 
use clinical and demographic participant baseline char-
acteristics and time to event outcome data.
To assess statistical heterogeneity, we will assess I226 
derived from two- stage meta- analysis models, with 0% 
indicating no heterogeneity, 25% low heterogeneity, 50% 
moderate heterogeneity and 75% as being high hetero-
geneity.26 A 95% prediction interval will be calculated to 
evaluate the potential range of the treatment effect when 
applied in an individual study setting.28
Missing data
The percentage of individual participant missing data 
(baseline characteristics, event status and time to event or 
censoring) will be recorded for each study. We plan to use 
multiple imputation on participant baseline characteristics 
which are missing individually within studies reporting the 
specified characteristic61 and a sensitivity analysis would be 
performed using observed and imputed data.
Sensitivity analysis
To assess whether various sources of heterogeneity affect 
the overall effect size and the robustness of the IPD find-
ings, we will conduct sensitivity analyses. Sources of hetero-
geneity, including study level characteristics such as the risk 
of bias, year of publication, setting (community, primary or 
secondary care), duration of follow- up, country of study, 
will be explored. We will also explore differences between 
one and two- stage IPD meta- analytic approaches.62
Aggregate data meta-analysis
We will investigate the possibility of inclusion bias by 
reporting the characteristics of eligible trials for which 
data were sought but not obtained. If suitable results 
are available for these studies, we will perform two- stage 
meta- analyses to incorporate the results of these trials 
with those of the trials where IPD was obtained. Potential 
publication bias will be estimated by funnel plot inspec-
tion and by use of Egger’s test for asymmetry.63
Predictors and moderators
To investigate the effects of baseline participant characteris-
tics on relapse regardless of the psychological intervention 
offered (research question 2), each of the predictors will be 
entered into a time- to- event model with the predictor as the 
independent variable (together with treatment allocation) 
and time to relapse as the dependent variable. To account 
for clustering of patients within a study we will include a 
study as a variable within the model, either as a random or 
fixed effect. Individual predictor v will be selected based on 
p values. We will initially include variables that are associ-
ated with the outcome with p<0.10, in regression models, 
including an individual variable and treatment allocation 
only. These variables will then be combined in a further 
model; any variables with p>0.05 will then be removed, 
which follows the criteria by Heffner et al64 as described 
in Ahmed et al.65 Each variable that has been removed will 
then be added individually to the model where all variables 
have p<0.05 and will be included if their p value is <0.05. 
In this way, predictors of time to depressive relapse will be 
identified. We will also assess the model fit by Akaike’s Infor-
mation Criterion.66
To investigate differential treatment effects across 
different participant subgroups (research question 3), 
we will perform a series of models adding the interaction 
term between each moderator and treatment allocation 
(each model will include only one interaction effect). In 
the two- stage model, we will first estimate the interaction 
at study level and will then combine interaction estimates 
in a random effects- meta- analysis. Potential moderators 
will be centred within the study to avoid ecological bias; 
continuous covariates will be centred around the study 
mean; binary covariates will be centred around the propor-
tion with the characteristic.28 67 Treatment allocation for 
the above model will be categorised by psychological inter-
vention versus non- psychological intervention in the first 
instance.
dIsCussIOn
This IPD meta- analysis can provide up to date treatment 
efficacy estimates and has the potential to establish whether 
there are any moderators and predictors of treatment effect. 
This could help answer the ‘what works for whom’ question 
we are hoping to answer. The IPD has several strengths, first 
it allows us to look at individual- level data rather than study- 
level data which give us the possibility to assess whether 
specific baseline and treatment characteristics predict or 
moderate time to relapse with more specificity and more 
power. Moreover, we will be able to study our outcome of 
interest more precisely, using the individual time to event 
data rather than aggregate information presented at study 
level.68 Various factors may hamper the process and inter-
pretation of an IPD meta- analysis. There may be inconsisten-
cies across studies regarding which variables are reported, 
and how they are reported, thus limiting our ability to assess 
the effect of these potential predictors and moderators of 
treatment. There may be some inclusion bias, as we may not 
be able to obtain IPD for all eligible studies; however, where 
possible, sensitivity analyses with the inclusion of published 
aggregate data will address this issue.
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This is to our knowledge the first IPD meta- analysis that 
attempts to establish the effects of a range of psycholog-
ical relapse prevention strategies compared with control 
conditions, as well as assessing whether any predictors or 
moderators might affect the risk of relapse for patients 
receiving a psychological intervention or a control 
intervention.
This study has the potential to inform clinicians, 
healthcare providers and people who have had a previous 
episode of depression. Firstly on the relative effective-
ness of different approaches for prevention of depressive 
relapse and secondly this study may also offer further 
indications on overall risk factors and what may work for 
whom in preventing relapse for patients who have experi-
enced a previous episode of depression.
Ethics and dissemination
We will disseminate the work via peer review publications. 
Day to day oversight and management of the database will 
be by JB and analyses will be conducted by JB and FCW. 
The dataset is not open access. Researchers may poten-
tially receive access to the database on request pending 
on institutional approvals on data transfer and ethics and 
approval of all the collaborating co- authors for sharing the 
data beyond the ITFRA consortium. Patient privacy will be 
ensured by adhering to the Amsterdam University Medical 
Centre—location AMC guidance on research participant 
data management and storage. This covers a range of data 
protection and storage measures including (1) setting up 
inter- institutional data sharing agreements prior to data 
sharing, (2) sharing only pseudonymised (de- identified) 
data, (3) secure data sharing and data storage.
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